Survival Strategies for BD in Innovative Medical Device Companies: Insights from China Innovation Healthcare Asset Salon | Episode 2

With over 15 years of experience in project management and business development (BD) transaction management within the medical device industries of both China and the United States, Ronnie currently serves as a Partner at Tongda Capital and Accesstech, and is the Co-founder of the ONE Investment Club. Recent transaction projects he has been involved in include Zhenyi, Changyida, Innovheart, Xeltis, and Merion. Prior to entering the investment banking sector, Ronnie focused on program management for multiple MedTech companies across China and the U.S., participating in several cutting-edge innovation projects such as heart valve stents, drug-eluting stents, inferior vena cava filters, thrombectomy stents, and flow diverters. Ronnie holds more than ten patents related to biomedical engineering and is a licensed Professional Engineer (PE) in the State of California. He earned a Master of Science degree in Bioengineering from San Diego State University, with a research focus on medical devices.

Responsible for bioeconomy research, business development, investment, and post-investment management. Holds a Master’s degree in Biology from the Chinese Academy of Sciences, with a focus on biotechnology industry research and investment opportunity sourcing. Previously served as Deputy Director of the Healthcare Investment and Business Development Department at Aoyin Capital and as Senior Manager at Sanofi Pasteur.

Previously worked at the Chinese Academy of Sciences, conducting research on “marine microbial natural products and the biosynthesis of their secondary metabolites,” and published several SCI papers, including in Angewandte Chemie International Edition (Top 1), as well as multiple patents. Recognized by the Fund-of-Funds Research Center as one of the “40 Under 40 Most Promising Young Direct Investment Fund Investors.” Awarded the “Annual Young Healthcare Investor” title under the Weilan Awards of VCBeat’s Future Healthcare 100 List.

Responsible for Medtronic’s local innovation partnerships and strategic planning in China, Ms. Le Lei has established strategic collaborations with multiple leading domestic innovative enterprises in specialized fields, thereby advancing Medtronic’s localization and ecosystem strategy. She has held key roles across various functions within Medtronic globally and in the Greater China region, driving numerous strategic investment projects worldwide. Ms. Le holds an MBA in Healthcare Management from the Wharton School of the University of Pennsylvania.

He earned his bachelor’s, master’s, and doctoral degrees in Aircraft Design from Northwestern Polytechnical University. In 2015, he went to the United States as a state-sponsored joint-training Ph.D. student, where he began researching vascular intervention technologies and concurrently conducted research at Brookhaven National Laboratory for two years. After completing his Ph.D., he joined the Department of Mechanical Engineering at Tsinghua University as a postdoctoral researcher. His research achievements received the First Prize in the Second “Yuanchuang Cup” National Innovation and Creativity Competition. In recent years, he has served as principal investigator for the National Natural Science Foundation of China Youth Fund Project and has played a key role in several major initiatives, including the National 14th Five-Year Plan Key R&D Program, the Central Military Commission’s National Innovation Special Zone Key Exploration Project, and the Beijing Natural Science Foundation’s Non-Consensus Project. He has published more than 20 high-impact papers in SCI-indexed journals and international conferences, and holds 23 granted invention patents.

With 20 years of experience in the R&D and industrialization of orthopedic surgical robots, he was deeply involved in the development and commercialization of China’s first orthopedic surgical robot. He performed China’s first robot-assisted orthopedic surgery (2004) and the first remote orthopedic surgery (2006). He was awarded the “2025 Surgical Robot Entrepreneur Award.” He is a rare high-level leading talent in China with an interdisciplinary medical-engineering R&D background and extensive industrialization experience in orthopedic surgical robots.